Nova Leap Health (NLH) AI Stock Analysis

• Market Cap: C$30.56M
• Dividend Yield: N/A
• Average Volume (3M): 25.81K
• Price to Earnings (P/E): 184.2
• Beta (1Y): 0.62
• Revenue Growth: 11.89%
• EPS Growth: 5.56%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): >-0.01
• Shares Outstanding: 87,314,255
• 10 Day Avg. Volume: 33,608
• 30 Day Avg. Volume: 25,813
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$0.50
• Price Target Upside: 42.86% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 61 Neutral
• Price Target: C$0.50 ▲(42.86% Upside)

Nova Leap Health's stock score is primarily influenced by its financial performance and technical analysis. The company shows improved profitability and positive stock momentum, but challenges in revenue growth and a high P/E ratio suggest caution. The absence of earnings call data and corporate events limits further insights.

Nova Leap Health Business Overview & Revenue Model

Company Description

Nova Leap Health Corp. provides home and home health care services in the United States and Canada. Its services include dementia care, companionship, personal and respite care, cooking and meal preparation, bathing, dressing, grooming, housekeeping, errands, transportation, and medication reminders by nursing staff. Nova Leap Health Corp. was incorporated in 2015 and is headquartered in Halifax, Canada.

How the Company Makes Money

Nova Leap Health makes money primarily through the provision of home health care services. Revenue is generated by offering personalized care plans tailored to individual client needs, which can include assistance with daily living activities, companionship, and specialized care for those with chronic or acute health conditions. The company leverages strategic acquisitions of small to mid-sized home care businesses to expand its market presence and increase its client base. Additionally, Nova Leap Health may engage in partnerships or collaborations with healthcare providers and institutions to enhance service offerings and optimize care delivery, contributing to its revenue growth.

Nova Leap Health Financial Statement Overview

Summary

Nova Leap Health shows mixed financial performance with improved profitability in 2024, supported by a strong equity position and low leverage. However, revenue growth challenges and decreased operating cash flow indicate areas for improvement.

Income Statement

Nova Leap Health has demonstrated fluctuations in revenue with a notable decline from $28.2M in 2022 to $25.8M in 2024. Gross profit margin has remained relatively stable, yet net income turned positive in 2024 at $1.38M from a loss in previous years, indicating improved profitability. EBIT and EBITDA margins are positive but show room for enhancement, highlighting potential operational efficiency improvements.

Balance Sheet

The company maintains a healthy equity base with an equity ratio of approximately 81.5% in 2024. The debt-to-equity ratio is relatively low at 0.14, suggesting manageable leverage. Return on equity improved significantly in 2024, reflecting enhanced profitability and effective use of equity.

Cash Flow

Operating cash flow decreased to $1.39M in 2024 from $2.15M in 2023, reflecting potential challenges in cash generation from operations. However, the company maintains positive free cash flow. The operating cash flow to net income ratio is strong at 1.01, indicating efficient conversion of income to cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	28.11M	25.76M	26.18M	28.21M	21.28M	17.31M
Gross Profit	11.00M	9.89M	9.77M	9.98M	7.21M	5.87M
EBITDA	1.23M	2.50M	994.47K	420.35K	4.76M	2.36M
Net Income	116.09K	1.38M	-1.05M	-835.75K	1.76M	1.26M
Balance Sheet
Total Assets	23.59M	22.39M	20.90M	23.95M	26.77M	17.54M
Cash, Cash Equivalents and Short-Term Investments	1.39M	1.40M	894.76K	1.27M	1.73M	2.78M
Total Debt	3.27M	2.53M	1.40M	3.97M	6.20M	5.96M
Total Liabilities	4.93M	4.14M	2.70M	5.27M	8.29M	7.69M
Stockholders Equity	18.66M	18.25M	18.20M	18.68M	18.48M	9.84M
Cash Flow
Free Cash Flow	1.41M	1.36M	2.13M	949.49K	2.18M	3.01M
Operating Cash Flow	1.43M	1.39M	2.15M	1.02M	2.18M	3.01M
Investing Cash Flow	-2.58M	-1.59M	-23.13K	-56.24K	-7.40M	-1.56M
Financing Cash Flow	1.37M	729.78K	-2.52M	-1.41M	4.33M	-325.46K

Nova Leap Health Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.35
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:NLH, the sentiment is Positive. The current price of 0.35 is above the 20-day moving average (MA) of 0.32, above the 50-day MA of 0.29, and above the 200-day MA of 0.27, indicating a bullish trend. The MACD of 0.01 indicates Negative momentum. The RSI at 60.25 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:NLH.

Nova Leap Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NLH	61 Neutral	C$30.56M	184.21	0.69%	―	11.89%	5.56%
CRRX	53 Neutral	219.43M	-117.91	-2.09%	0.57%	-0.16%	75.25%
NUMI	41 Neutral	13.86M	-0.45	-2707.75%	―	―	―
PHA	41 Neutral	1.94M	-0.17	233.69%	―	-22.61%	7.72%
JNH	34 Underperform	413.49K	-0.10	―	―	22.44%	-3.91%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Nova Leap Health Corporate Events

Nova Leap Health Corp. Reports Record Q2 2025 Financial Results

Nova Leap Health Corp. announced record financial results for Q2 2025, showcasing significant growth across all major financial metrics, including revenue, gross margin, and Adjusted EBITDA. The company’s performance was bolstered by both organic growth and a recent acquisition in Nova Scotia, highlighting its operational discipline and innovative approach, which includes leveraging AI and fintech. Despite the strong financial performance, the company’s share price and trading activity remain disconnected from its underlying fundamentals, though insider confidence is high with increased ownership.

The most recent analyst rating on (TSE:NLH) stock is a Buy with a C$0.60 price target. To see the full list of analyst forecasts on Nova Leap Health stock, see the TSE:NLH Stock Forecast page.